Capricor Therapeutics Gets an FDA Panel Date for Duchenne Cell Therapy Deramiocel

Capricor Therapeutics is heading into the most important stretch of its history, with a regulatory panel now on the calendar.

Capricor is a Nasdaq-listed cell-therapy company whose lead candidate, deramiocel, is an investigational treatment for Duchenne muscular dystrophy, a fatal genetic disease that progressively weakens the muscles of young boys, including the heart.

On June 26 the company said the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will meet on July 29, 2026 to review its biologics license application for deramiocel, with the agency's target action date set for August 22, 2026. The filing rests on the Phase 2 HOPE-2 trial and its long-term extension, plus the Phase 3 HOPE-3 study, which the company says met its primary endpoint measuring skeletal muscle function and a key secondary endpoint measuring heart function. An advisory committee gives outside experts a public forum to weigh the evidence ahead of the decision.

Advisory panels can vote against a program, and a negative recommendation or a complete response letter would be a serious blow to a company that leans heavily on this single asset.

This is market commentary, not investment advice — small-cap biotech stocks are highly speculative and you can lose your entire investment.